-
Rare inherited bleeding disorders in The Middle East Transfus. Med. Rev. (IF 4.5) Pub Date : 2024-03-15 Arefeh Mazhari, Maryam Khajavi, Hassan Mansouritorghabeh
-
Increased serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized healthy donors with G-CSF: a cohort study Transfus. Med. Rev. (IF 4.5) Pub Date : 2024-03-15 Joan Cid, Katia Guinetti-Ortiz, Paola Charry, Gloria Carbassé, Mar de Pablo-Miró, Laura Rubia, Marta Garcia, Jose Alcaraz-Quiles, Enric Cascos, Nuria Martínez-Cibrian, María Queralt Salas, Maria Suárez-Lledó, Laura Rosiñol, Francesc Fernández-Avilés, Carmen Martínez, Montserrat Rovira, Miquel Lozano
Limited data regarding elevation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized donors with G-CSF is available. We extended these findings by examining serum NT-proBNP in a cohort study including 35 healthy donors and 69 patients who received G-CSF for CD34+ mobilization as well as 54 patients who did not receive G-CSF but who underwent collection of CD3+ cells for chimeric antigen
-
Examining Injustices: Transfusion Medicine and Race Transfus. Med. Rev. (IF 4.5) Pub Date : 2024-02-18 Sumedha Arya, Alyson Mahar, Jeannie Callum, Richard L. Haspel
Race and ethnicity are sociopolitical and not biological constructs, and assertions that these population descriptors have scientific meaning has caused significant harm. A critical assessment of the transfusion medicine literature is an important aspect of promoting race-conscious as opposed to race-based medicine. Utilizing current definitions and health equity frameworks, this review will provide
-
Natural history studies, a natural next step to study emerging transfusion-transmitted infections† Transfus. Med. Rev. (IF 4.5) Pub Date : 2024-01-17 Maureen J. Miller, Lara Perinet, Harvey J. Alter, Kathleen Conry-Cantilena, Valeria De Giorgi
Abstract not available
-
-
Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-12-22 Elizabeth Abels, Brian D. Adkins, Koraima Cedeno, Garrett S. Booth, Elizabeth S. Allen, Laura D. Stephens, Jennifer S. Woo, Christopher A. Tormey, Jeremy W. Jacobs
The current recommended testing algorithm for assessing the alloimmunized pregnancy utilized by many obstetricians in the United States (US) fails to consider the most recent evidence, placing fetuses, and mothers at unnecessary risk of poor outcome or death. This narrative review of the current landscape of fetal red blood cell (RBC) antigen testing evaluates the history of hemolytic disease of the
-
Blood Donor Incentives across 63 Countries: The BEST Collaborative Study Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-12-16 Caroline Graf, Krystal Oteng-Attakora, Eamonn Ferguson, Ralph Vassallo, Eva-Maria Merz
Incentives for blood donors are a much-debated strategy intended to ensure a sufficient supply of blood. Yet, there is a fundamental lack of knowledge about which incentives are offered by different blood collectors. We provide a comprehensive description of incentive policies for whole blood donors across 63 countries and 50 states of the United States. We collected data on incentive policies by conducting
-
Recommended Papers of 2023 From the TMR Editorial Board Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-12-12 Sunny Dzik, Mike Murphy, Zoe McQuilten, Jeannie Callum
Abstract not available
-
-
Prehospital Freeze-Dried Plasma in Trauma: A Critical Review Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-11-30 William P. Sheffield, Kanwal Singh, Andrew Beckett, Dana V. Devine
Major traumatic hemorrhage is now frequently treated by early hemostatic resuscitation on hospital arrival. Prehospital hemostatic resuscitation could therefore improve outcomes for bleeding trauma patients, but there are logistical challenges. Freeze-dried plasma (FDP) offers indisputable logistical advantages over conventional blood products, such as long shelf life, stability at ambient temperature
-
-
Advancing Understandings of Blood Donation Motivation and Behavior Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-11-02 Shana D. Hughes, Christopher L. France, Kamille A. West-Mitchell, Theresa Pina, Duncan McElfresh, Merlyn Sayers, Barbara J. Bryant
In this review, we provide critical analysis of social science research into blood donation motivation and behavior. We first share an understanding of the existing literature and recommendations for future research collectively developed by members of the Working Group on Blood Donors and the Supply: Diversifying while Maintaining the Donor Pool, Donor Selection, and Optimizing Blood Availability
-
Selected Topics From the State of the Science in Transfusion Medicine: Key Insights on Current Progress and Future Directions Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-11-01 Nareg H. Roubinian, Brian Custer
Abstract not available
-
Current Insights Into K-associated Fetal Anemia and Potential Treatment Strategies for Sensitized Pregnancies Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-15 Margaret C. Carpenter, Scarlett C. Souter, Ronnie J. Zipkin, Margaret E. Ackerman
K-associated anemic disease of the fetus and newborn (K-ADFN) is a rare but life-threatening disease in which maternal alloantibodies cross the placenta and can mediate an immune attack on fetal red blood cells expressing the K antigen. A considerably more common disease, D-associated hemolytic disease of the fetus and newborn (D-HDFN), can be prophylactically treated using polyclonal α-D antibody
-
Prevention of Rhesus-D Alloimmunization in the First Trimester of Pregnancy: Economic Analysis of Three Management Strategies Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-14 Vincent Dochez, Camille Chabernaud, Solène Schirr-Bonnans, Valéry-Pierre Riche, Thibault Thubert, Norbert Winer, Solène Vigoureux
Anti-D alloimmunization in the first trimester of pregnancy has long been the subject of prevention with anti-D immunoglobulins during events at risk of fetomaternal hemorrhage. Although the efficacy of preventing anti-D alloimmunization by an injection of immunoglobulin at 28 weeks of gestation (WG) is obvious, the literature provides little evidence of the effectiveness before 12+6 WG and several
-
-
Medication Deferrals in Blood Donors Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-12 Mindy Goldman, Cyril Jacquot, Kevin Land
Medication use is extremely common in blood donors. Blood centers use various methods to obtain a history of medication use, all of which have strengths and weaknesses. Some data are available to develop policies for medications that impact product quality, transmissible disease testing, and infectious risks. Many blood centers defer donors for use of a small number of highly teratogenic medications
-
Next Generation Sequencing of Red Blood Cell Antigens in Transfusion Medicine: Systematic Review and Meta-Analysis Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-07 Carolina Guimarães Ramos Matosinho, Caroline Graciane Rodrigues Silva, Marina Lobato Martins, Maria Clara Fernandes Silva-Malta
Molecular analysis of blood groups is important in transfusion medicine, allowing the prediction of red blood cell (RBC) antigens. Many blood banks use single nucleotide variant (SNV) based methods for blood group analysis. While this is a well-established approach, it is limited to the polymorphisms included in genotyping panels. Thus, variants that alter antigenic expression may be ignored, resulting
-
Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-04 Evan M. Bloch, Michael P. Busch, Laurence M. Corash, Roger Dodd, Benyam Hailu, Steve Kleinman, Sheila O'Brien, Lyle Petersen, Susan L. Stramer, Louis Katz
The tragedy of transfusion-associated hepatitis and HIV spurred a decades-long overhaul of the regulatory oversight and practice of blood transfusion. Consequent to improved donor selection, testing, process control, clinical transfusion practice and post-transfusion surveillance, transfusion in the United States and other high-income countries is now a very safe medical procedure. Nonetheless, pathogens
-
Blood Demand Forecasting and Supply Management: An Analytical Assessment of Key Studies Utilizing Novel Computational Techniques Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-10-02 Na Li, Tho Pham, Calvino Cheng, Duncan C. McElfresh, Ryan A. Metcalf, W. Alton Russell, Rebecca Birch, James T. Yurkovich, Celina Montemayor-Garcia, William J. Lane, Aaron A.R. Tobian, Nareg Roubinian, Jansen Seheult, Ruchika Goel
Use of data-driven methodologies in enhancing blood transfusion practices is rising, leveraging big data, machine learning, and optimization techniques to improve demand forecasting and supply chain management. This review used a narrative approach to identify, evaluate, and synthesize key studies that considered novel computational techniques for blood demand forecasting and inventory management through
-
Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-09-25 Paola Mina-Osorio, Minh-Ha Tran, Ali A. Habib
Therapeutic plasma exchange (TPE or PLEX) is used in a broad range of autoimmune diseases, with the goal of removing autoantibodies from the circulation. A newer approach for the selective removal of immunoglobulin G (IgG) antibodies is the use of therapeutic molecules targeting the neonatal Fc receptor (FcRn). FcRn regulates IgG recycling, and its inhibition results in a marked decrease in circulating
-
-
Involvement of Diverse Populations in Transfusion Medicine Research Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-09-20 Yvette Marie Miller, Sara Bakhtary, Stella T. Chou, Benyam Hailu, Rita A. Reik, Raven Hardy Richard, Bryan R. Spencer, Rena Witherspoon, Meghan Delaney
Communities of color and diverse communities (eg, race, socioeconomic status, language, sexual orientation etc.) have not been recruited and enrolled equitably to participate in research studies in transfusion medicine. The exclusion of diverse communities in transfusion research can lead to health disparities lack of access to approved therapeutics and unequal allocation of interventions, resulting
-
Optimizing Informed Consent Discussions: Developing a Narrative for Transfusion Consent Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-09-09 Michelle P. Zeller, Marissa Laureano, Aditi Khandelwal, Shannon J. Lane, Richard Haspel, Mark Fung
Ensuring patient informed consent is a key tenet of modern medicine. Although transfusion of blood products is among the most common medical procedures performed in hospitalized patients, there is evidence that informed consent for transfusion is at times incomplete, poorly understood, hurried, and/or inaccurate. This study aimed to develop a narrative that can be used as a framework for practicing
-
Optimizing RBC Transfusion Outcomes in Patients with Acute Illness and in the Chronic Transfusion Setting Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-09-09 Ross M. Fasano, Allan Doctor, Sean R. Stowell, Philip C. Spinella, Jeffrey L. Carson, Cheryl L. Maier, Cassandra D. Josephson, Darrell J. Triulzi
Red blood cell (RBC) transfusion is a common clinical intervention used to treat patients with acute and chronic anemia. The decision to transfuse RBCs in the acute setting is based on several factors but current clinical studies informing optimal RBC transfusion decision making (TDM) are largely based upon hemoglobin (Hb) level. In contrast to transfusion in acute settings, chronic RBC transfusion
-
Acute Chest Syndrome in Sickle Cell Disease Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-09-03 Neha Bhasin, Ravi Sarode
Acute chest syndrome (ACS) is the leading cause of mortality among individuals with sickle cell disease (SCD) accounting for 25% of all deaths. The etiologies and clinical manifestations of ACS are variable among children and adults, with a lack of clear risk stratification guidelines for the practicing clinician. In addition, the management of ACS is based on limited evidence and is currently guided
-
HIV Pre-Exposure Prophylaxis, Blood Donor Deferral, Occult Infection, and Risk of HIV Transmission by Transfusion: A Fine Balance Between Evidence-Based Donor Selection Criteria and Transfusion Safety Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-08-22 Jean-François Leblanc, Brian Custer, Thijs Van de Laar, Steven J. Drews, Marc Germain, Antoine Lewin
Pre- and postexposure prophylaxis for human immunodeficiency virus (HIV) are key to reducing the transmission of this virus. Furthermore, low-toxicity, long-acting formulations provide additional clinical benefits, in particular easier adherence to treatment and prevention. However, breakthrough HIV infections can occur despite the use of pre-exposure prophylaxis (PrEP), mainly due to suboptimal adherence
-
Battle of the (Chat)Bots: Comparing Large Language Models to Practice Guidelines for Transfusion-Associated Graft-Versus-Host Disease Prevention Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-08-19 Laura D. Stephens, Jeremy W. Jacobs, Brian D. Adkins, Garrett S. Booth
Published guidelines and clinical practices vary when defining indications for irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease (TA-GVHD). This study assessed irradiation indication lists generated by multiple artificial intelligence (AI) programs, or chatbots, and compared them to 2020 British Society for Haematology (BSH) practice guidelines.
-
Performance of Femoral and Internal Jugular Venous Catheters for Collection and Transplantation of Peripheral Blood Stem Cells in Adults Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-08-19 Tatsanee Aiemsak, Jutarat Suriyachai, Wisakha Kaewprachum, Thachamon Sinsoongsud, Yupawan Iamborisut, Thanakrit Piyajaroenkij, Sulada Pukiat, Teeraya Puavilai, Pimjai Niparuck
Abstract not available
-
Prophylactic Platelet Transfusion: Is There Evidence of Benefit, Harm, or No Effect? Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-08-02 Cheryl L. Maier, Simon J. Stanworth, Martha Sola-Visner, Daryl Kor, Allan E. Mast, Ross Fasano, Cassandra D. Josephson, Darrell J. Triulzi, Marianne E. Nellis
The optimal use of prophylactic platelet transfusion remains uncertain in a number of clinical scenarios. Platelet count thresholds have been established in patients with hematologic malignancies, yet thresholds backed by scientific data are limited or do not exist for many patient populations. Clinical scenarios involving transfusion thresholds for thrombocytopenic patients with critical illness,
-
Red Blood Cell Storage: From Genome to Exposome Towards Personalized Transfusion Medicine Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-08-02 Angelo D'Alessandro, Eldad A. Hod
-
Blood Group Serology and “Race”: Looking Back to Move Forward Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-07-15 Richard L. Haspel, William H. Schneider, Sunitha Vege, Patricia A.R. Brunker
Less than a decade after the discovery of the ABO antigens as a Mendelian inherited trait, blood group antigen frequencies were first used to define racial groups. This approach, known as seroanthropology, was the basis for collecting large amounts of blood group frequency data in different populations and was also sometimes used for racist purposes. Ultimately, population geneticists used these data
-
Biphosphoglycerate Mutase: A Novel Therapeutic Target for Malaria? Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-07-13 Alessia Azzuolo, Yunxiang Yang, Albert Berghuis, Nassima Fodil, Philippe Gros
Biphosphoglycerate mutase (BPGM) is a tri-functional enzyme expressed exclusively in erythroid cells and tissues that is responsible for the production of 2,3-biphosphoglycerate (2,3-BPG) through the Rapoport-Luebering shunt. The 2,3-BPG is required for efficient glycolysis and ATP production under anaerobic conditions, but is also a critical allosteric regulator of hemoglobin (Hb), acting to regulate
-
Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-06-16 Alexis Pozzo di Borgo, Samuel Rochette, Amaury Gaussen, Sheila F. O'Brien, Marc Germain, Christian Renaud, Antoine Lewin
Secondary transmission of variant Creutzfeldt-Jakob disease (vCJD) can occur through blood transfusion or receipt of plasma-derived products. However, published reviews on this topic are outdated, focused on a single country or product type, or did not comprehensively review modeling studies on the risk of transfusion-transmission. We reviewed existing data on observed and modeled risks of transfusion-transmission
-
-
-
Understanding Intraoperative Transfusion Decision-Making Variability: A Qualitative Study Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-05-19 Tori Lenet, Joseph Tropiano, Stephanie Skanes, Victoria Ivankovic, Michael Verret, Daniel I McIsaac, Alan Tinmouth, Stuart G Nicholls, Andrea M Patey, Dean A Fergusson, Guillaume Martel
There is evidence of significant intraoperative red blood cell (RBC) transfusion variability that cannot be explained by case-mix, and may reflect unwarranted transfusions. The objective was to explore the source of intraoperative RBC transfusion variability by eliciting the beliefs of anesthesiologists and surgeons that underlie transfusion decisions. Interviews based on the Theoretical Domains Framework
-
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-05-17 Nicola Piccirillo, Rossana Putzulu, Elisabetta Metafuni, Giuseppina Massini, Federica Fatone, Andrea Corbingi, Sabrina Giammarco, Maria Assunta Limongiello, Alessia Di Giovanni, Gina Zini, Andrea Bacigalupo, Luciana Teofili, Simona Sica, Patrizia Chiusolo
Allogeneic peripheral blood stem cells mobilization is now the basis of most stem cell transplants. In a very limited number of cases, mobilization is suboptimal leading to further collection procedures, to suboptimal cell doses infusion with delayed engraftment time, increased risks of transplant procedure and of related costs. To date we have no recognized and shared criteria for early estimating
-
Corrigendum to “Pioneers & Pathfinders: Canadian Surgeons and the Introduction of Blood Transfusion in War Surgery” [Transfus Med Rev 2008; 22: 77-86] Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-04-19 Pinkerton PH
Abstract not available
-
-
RESPONSE OF LYMPHOPENIC PLATELETPHERESIS DONORS TO COVID-19 VACCINATION Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-03-13 Renee Bazin, Annemarie Laumaea, Antoine Lewin, Debashree Chatterjee, Carl Simard, Tony Tremblay, Pascal Rouleau, Marie-Eve Allard, Josee Perreault, Andres Finzi
Abstract not available
-
Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients: A Within-trial Economic Evaluation of the FIBRES Randomized Controlled Trial Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-03-13 Lusine Abrahamyan, Fleur Doudney, George Tomlinson, Jeannie Callum, Steven Carcone, Deep Grewal, Justyna Bartoszko, Murray Krahn, Keyvan Karkouti
Abstract not available
-
SARS-CoV-2 Seroprevalence in the Vaccine Era: The Canadian Blood Services Serosurvey January to November 2021 Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-03-13 Sheila O'Brien, Cassandra Reedman, Qi-Long Yi, Steven Drews
Abstract not available
-
Assessment of Hemoglobin-Oxygen Affinity of RBCs of Different Senescence Levels During Hypothermic Storage in Old Senior and Teenage Donors Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-03-13 Mahsa Yazdanbakhsh, Rafay Osmani, Carly Olafson, April Xu, Tamir Kanias, Olga Mykhailova, Jason Acker
Abstract not available
-
Red Blood Cell Sublethal Damage: Hemocompatibility Is not the Absence of Hemolysis Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-03-14 Antony P. McNamee, Michael J. Simmonds
Blood is a complex fluid owing to its two-phase suspension of formed cellular elements within a protein-rich plasma. Vital to its role in distributing nutrients throughout the circulatory system, the mechanical properties of blood – and particularly red blood cells (RBC)—primarily determine bulk flow characteristics and microcirculatory flux. Various factors impair the physical properties of RBC, including
-
-
Artificial Intelligence and Scholarship in the 21st Century Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-02-24 Sunny Dzik, Michael Murphy, Rachel Garland
Abstract not available
-
Journal Club Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-02-11 Simon J Stanworth, Johnathan P Mack, John D Roback, Mark Fung
Abstract not available
-
Reported Seroprevalence of Transfusion-Transmitted Infections in Voluntary and Replacement Donors Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-02-07 Ghulam Rasool, Arif Muhammad Khan, Imran Riaz Malik, Muhammad Riaz, Imtiaz Mahmood Tahir, Aziz Ur Rehman, Mazhar Abbas
Abstract not available
-
Biotinylated Platelets: A Promising Labeling Technique? Transfus. Med. Rev. (IF 4.5) Pub Date : 2023-01-13 Stefan F. van Wonderen, Floor L.F. van Baarle, Sanne de Bruin, Anna L. Peters, Dirk de Korte, Robin van Bruggen, Alexander P.J. Vlaar
Labeling of platelets (PLTs) is essential for research purposes, in order to measure the recovery and survival of transfused PLTs in vivo. Biotinylation is a promising new alternative to the gold standard of radioactive labeling. This review highlights 4 key publications that provide significant insights into biotin-labeled PLTs (bioPLTs). Stohlawetz et al. established that transfusion of bioPLTs in
-
Alloantigen Copy Number as a Critical Factor in RBC Alloimmunization Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-12-23 Seema R. Patel, Cheryl L. Maier, James C. Zimring
RBC alloimmunization remains a significant barrier to ongoing transfusion therapy leading to morbidity, and in extreme cases mortality, due to delayed or insufficient units of compatible RBCs. In addition, the monitoring and characterization of alloantibodies, often with multiple specificities in a single patient, consumes substantial health care resources. Extended phenotypic matching has mitigated
-
State of the Evidence: Drug Removal via Apheresis Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-12-20 Thomas C Binns, Nataliya Sostin, Christopher A Tormey
Therapeutic apheresis refers to a diversity of procedures in which specific hematologic components (e.g., plasma, erythrocytes, leukocytes, etc.) with pathological associations are removed from circulation (with possible replacement) in order to treat a variety of disease processes. As pharmacologic agents also circulate with these components, their removal is sometimes incidental, or in the scenario
-
Recommended Papers of 2022 From the TMR Editorial Board Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-12-17 Sunny Dzik, Michael Murphy
Abstract not available
-
-
Eligibility Considerations for Female Whole Blood Donors: Hemoglobin Levels and Iron Status in a Nationally Representative Population Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-11-26 Bryan R. Spencer, Jodie L. White, Eshan U. Patel, Ruchika Goel, Evan M. Bloch, Aaron AR Tobian
Blood collection from minority populations improves the transfusion support of patients with sickle cell disease and thalassemia, but efforts are challenged by high deferral rates for hemoglobin (Hb) eligibility thresholds. This study sought to evaluate hemoglobin and iron status of a representative US female population to assess the suitability of 12.0 g/dL as minimum hemoglobin. Data were extracted
-
-
Academic Productivity of Early Career Transfusion Medicine Specialists: A Workforce Study Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-10-29 Yvette C. Tanhehco, Tina S. Ipe, Garrett S. Booth, Brian D. Adkins
Blood Banking/Transfusion Medicine (BB/TM) specialists oversee all aspects of blood component transfusions and are often involved with apheresis, coagulation, and cellular therapy services as well. This study characterizes the BB/TM workforce to determine the scholarly productivity in the first 3 to 5 years after obtaining board certification and the impact of job type, job location, and academic rank
-
Monkeypox and Transfusion Safety Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-10-06 Roger Y. Dodd, Susan L. Stramer
In May of 2022, a multinational outbreak of monkeypox was recognized. It expanded rapidly and over the following three-plus months, more than 50,000 cases were reported from 100 countries, largely among gay or bisexual men. The causative agent is a poxvirus, related to smallpox and vaccinia viruses. Available information implies that the virus might be transfusion-transmissible, although no cases had
-
Plasma Exchange in Alzheimer's Disease Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-10-03 Lucas Rohrer, Muharrem Yunce, Thomas J. Montine, Hua Shan
Therapeutic plasma exchange (TPE) has traditionally been used to selectively remove pathologic contents including autoantibodies, abnormal proteins, immune complexes, or toxins from a patient's plasma. In addition to the removal of molecular contributors to disease, fluid replacement and infusion of beneficial plasma constituents including albumin can be tapered based on the pathophysiologic mechanisms
-
Emerging Therapies in Antiphospholipid Syndrome Transfus. Med. Rev. (IF 4.5) Pub Date : 2022-09-24 Anne Hubben, Keith R McCrae
The antiphospholipid syndrome (APS) is the most common cause of acquired immune-mediated thrombophilia. This syndrome is broadly defined by the presence of arterial or venous thrombosis, or pregnancy morbidity, in the presence of high levels of antiphospholipid antibodies. Despite recognition of this disorder more than 50 years ago, a fundamental unifying pathogenesis has not been determined. Due to